查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1744544

2032 年 CT/NG 测试市场预测：按产品、测试类型、最终用户和地区进行的全球分析

CT/NG Testing Market Forecasts to 2032 - Global Analysis By Product (Assays & Kits and Instruments/Analyzers), Testing Type (Laboratory Testing and Point-of-care (POC) Testing), End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的预测，全球 CT/NG 检测市场预计在 2025 年达到 21.6 亿美元，到 2032 年将达到 43.8 亿美元，预测期内的复合年增长率为 10.6%。

CT/NG检测是指用于检测世界上最常见的性行为感染（STI）－披衣菌感染披衣菌（CT）和淋病奈瑟菌（NG）的诊断性检测。这些检测对于早期诊断和治疗至关重要，因为这两种感染疾病通常无症状，但如果不及时治疗，可能会导致严重的健康问题，包括骨盆腔发炎和不孕症。 CT/NG检测通常使用核酸增幅检查（NAAT），可用于检测尿液检体、阴道拭子和其他检体，具有较高的敏感性和特异性。定期筛检是阻止这些感染疾病传播的重要公共卫生策略，尤其是在性活跃人群中。

根据美国疾病管制与预防中心 (CDC) 的数据，2023 年美国报告了超过 240 万例美国披衣菌感染、淋病和梅毒病例。披衣菌感染是最常见的性行为感染感染 (STI)，造成超过 160 万例。

性传染感染盛行率不断上升

推动CT/NG检测市场发展的主要因素之一是全球披衣菌感染和淋病盛行率的上升。根据美国疾病管制与预防中心（CDC）统计，光是2021年，美国就将通报超过70万例淋病和超过160万例披衣菌感染病例。由于无症状性感染者往往无法确诊，这些数字可能被低估。世界卫生组织（WHO）的数据显示，全球每年新增3.74亿例可治癒性感染疾病中，披衣菌感染和淋病占了很大一部分。由于疾病负担沉重，诊断检测的数量急剧增加，旨在阻止疾病进一步传播并儘早开始治疗。

昂贵的高级诊断测试

儘管核酸增幅检查(NAAT) 等先进诊断技术具有较高的灵敏度和特异性，但它们价格昂贵，可能会限制人们的获取，尤其是在中低收入国家。资金不足的公共卫生系统和小型诊所可能无法获得这些检测所需的昂贵试剂、专用设备和熟练的人员。这些经济障碍阻碍了性传染感染检测的普及，尤其是在性传染感染检测资金不足的地区。此外，自付费用也可能阻碍人们定期接受检测，尤其是对于没有医疗保险的人口和缺乏公共医疗保健系统的地区。

远端医疗与数位健康融合

远端医疗平台和数位健康解决方案的日益普及，为CT/NG检测开闢了新的途径。人们可以透过家用检测套组和基于应用程式的咨询，轻鬆、谨慎地获得性传染感染 (STI) 服务。这些平台可以支援电子处方、远端结果交付和样本采集预约。数位健康工具还能实现更精准的数据收集和接触者追踪，从而支持公共卫生监测。此外，诊断公司拥有将检测与数位支援服务捆绑在一起的长期机会，因为新冠疫情加速了这一趋势，表明患者和医疗保健提供者都越来越适应并接受虚拟医疗。

在资源匮乏的环境中与综合管理竞争

由于缺乏资金和实验室条件，许多开发中国家仍在广泛采用性传染感染的综合治疗。这种方法虽然准确性较低，但透过治疗症状而无需进行确认性检测，减少了诊断的必要性。继续采用综合治疗会危及扩大性传染感染/鼻咽癌检测的能力，尤其是在成本敏感的公共卫生系统中。此外，在最需要诊断的高负担国家，除非就地检验变得更容易获得併纳入现有程序，否则诊断的采用率可能仍然有限。

COVID-19的影响：

COVID-19 疫情以多种方式影响了 CT/NG 检测市场。最初，由于供应链中断、医疗系统负担过重以及检测资源被重新分配给 SARS-CoV-2 诊断，检测服务受到干扰。在许多地区，针对淋病和披衣菌感染等性传染感染的常规筛检项目被取消或缩减，导致检测量暂时下降，诊断延误。然而，疫情加速了照护现场诊断、远端医疗和自采集试剂套件的普及，为更便利、更分散的性传染感染检测奠定了基础。

预计在预测期内，检测和套件部分将成为最大的部分。

预计在预测期内，检测和套件领域将占据最大的市场占有率。这种主导地位得益于核酸增幅检查(NAAT) 等分子诊断检测的广泛应用，这些检测对识别 CT/NG 感染具有高度的敏感性和特异性。这些检测方法因其易于使用、週转时间短且适用于自动化平台，常用于临床实验室、医院，甚至是家用检测套组。此外，由于对早期准确诊断的需求日益增长，尤其是对于无症状性患者，基于检测的解决方案也越来越受欢迎。因此，该细分市场目前占据了市场收益的最大份额。

预计居家照护领域在预测期内将以最高复合年增长率成长

预计居家照护领域将在预测期内呈现最高成长率。这一成长的主要驱动力是对可近性、便利性和私密性性传染感染筛检日益增长的需求。远距远端医疗诊断服务和家用样本采集试剂套件越来越受欢迎，尤其是在新冠疫情改变了患者偏好之后。这些解决方案能够将样本送至认证实验室或无需前往医疗机构即可进行自我检测，从而提高了检测频率并减少了污名化。此外，自我检测的易用性、日益增强的认知度以及技术发展预计将显着推动该市场的成长。

占比最大的地区：

预计亚太地区将在预测期内占据最大市场占有率，这主要得益于该地区庞大的人口规模、不断上升的性传染感染率以及日益增强的性健康意识。此外，该地区市场主导地位的很大一部分原因在于中国、印度、日本和澳洲等国家日益普及的先进诊断技术、不断扩展的医疗基础设施以及政府倡议性传染感染筛检计画的支持。由于就地检验套件和核酸增幅检查(NAAT) 的使用日益增多，亚太地区市场正在不断扩张，使其成为全球最主要的CT/NG检测地区。

复合年增长率最高的地区：

预计北美地区在预测期内的复合年增长率最高。这得益于其强大的医疗保健体系、对性传染病的深入了解以及尖端诊断工具的广泛应用。完善的报销政策、日益增多的筛检倡议以及持续的研发投入，共同促进了市场的扩张。此外，灵敏快速的检测技术的普及，以及公共和私人部门对性健康计画的投资不断增加，也是支撑北美CT/NG检测市场强劲成长的部分因素。

免费客製化服务

订阅此报告的客户可享有以下免费自订选项之一：

  • 公司简介
    • 对其他市场公司（最多 3 家公司）进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 地理细分
    • 根据客户兴趣对主要国家市场进行估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 研究范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 限制因素
  • 机会
  • 威胁
  • 产品分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

第五章 全球 CT/NG 检测市场（按产品）

  • 检测方法和套件
  • 仪器/分析仪

6. 全球 CT/NG 检查市场（按检查类型）

  • 实验室测试
    • 核酸增幅检查（NAAT）
    • 免疫检测
    • 文化测试
  • 照护现场检验 (POC)
    • 快速诊断测试（RDT）
    • 自检检测套组

第七章全球 CT/NG 检查市场（按最终用户）

  • 诊断实验室
  • 医院和诊所
  • 居家照护环境
  • 其他最终用户

8.全球CT/NG检查市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第九章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十章 公司概况

  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific, Inc.
  • Binx Health, Inc.
  • Abbott Laboratories
  • Hologic Inc.
  • Siemens Healthineers AG
  • ELITech Group SAS
  • Danaher Corporation
  • Seegene, Inc.
  • Genetic Signatures Ltd.
  • Becton, Dickinson and Company（BD）
  • Qiagen NV
  • Meridian Bioscience Inc.
  • PerkinElmer Inc.
Product Code: SMRC29592

According to Stratistics MRC, the Global CT/NG Testing Market is accounted for $2.16 billion in 2025 and is expected to reach $4.38 billion by 2032 growing at a CAGR of 10.6% during the forecast period. CT/NG testing refers to diagnostic tests used to detect Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG), two of the most common sexually transmitted infections (STIs) worldwide. These tests are essential for early diagnosis and treatment because, although both infections frequently show no symptoms, if treatment is not received, they can cause major health problems like pelvic inflammatory disease and infertility. Typically, CT/NG testing uses nucleic acid amplification tests (NAATs), which can be carried out with urine samples, vaginal swabs, or other specimen types and have high sensitivity and specificity. Regular screening is a crucial public health tactic to stop the spread of these infections, particularly among sexually active people.

According to the Centers for Disease Control and Prevention (CDC), over 2.4 million cases of chlamydia, gonorrhea, and syphilis were reported in the United States in 2023. Chlamydia accounted for more than 1.6 million cases, making it the most commonly reported sexually transmitted infection (STI).

Market Dynamics:

Driver:

Growing STI prevalence

One of the major factors propelling the CT/NG testing market is the rising global incidence of chlamydia and gonorrhea. Over 700,000 cases of gonorrhea and over 1.6 million cases of chlamydia were reported in the United States in 2021 alone, according to the CDC. Because asymptomatic infections often go undiagnosed, these figures are probably underestimates. According to the World Health Organization (WHO), Chlamydia and gonorrhea account for a significant portion of the 374 million new curable STI infections that occur worldwide each year. In order to stop the disease from spreading further and to start treatment as soon as possible, diagnostic testing has increased dramatically as a result of this high disease burden.

Restraint:

Expensive advanced diagnostic testing

The high cost of advanced diagnostic technologies, like nucleic acid amplification tests (NAATs), can restrict access, particularly in low- and middle-income nations, despite their high sensitivity and specificity. Underfunded public health systems or smaller clinics may not be able to afford the costly reagents, specialized equipment, and skilled personnel needed for these tests. Widespread adoption is hampered by this financial obstacle, especially in places where STI testing funding is scarce. Moreover, the out-of-pocket expenses can also discourage people from getting tested on a regular basis, especially for populations without insurance or in areas without public healthcare systems.

Opportunity:

Integration of telemedicine and digital health

The increasing use of telemedicine platforms and digital health solutions is opening up new avenues for CT/NG testing. People can easily and discreetly access STI services with at-home testing kits and app-based consultations. These platforms can support electronic prescriptions for treatment, remote result delivery, and instructions for sample collection. Better data collection and contact tracing are also made possible by digital health tools, which support public health surveillance. Additionally, diagnostic companies have a long-term opportunity to bundle testing with digital support services, as the COVID-19 pandemic has accelerated this trend and demonstrated that both patients and providers are growing more at ease with virtual care.

Threat:

Competition in low-resource environments from syndromic management

Due to a lack of funding and access to laboratory testing, syndromic management of STIs is still widely used in many developing nations. This method reduces the need for diagnostics by treating symptoms without the need for confirmatory testing, despite being less accurate. The continued use of syndromic management jeopardizes CT/NG testing's ability to expand, particularly in public health systems where cost is a key consideration. Furthermore, diagnostic adoption may remain restricted in high-burden nations where it is most needed unless point-of-care tests become more accessible and incorporated into current procedures.

Covid-19 Impact:

The COVID-19 pandemic had a mixed effect on the CT/NG testing market. At first, it caused testing services to be disrupted because of supply chain disruptions, the overburden on the healthcare system, and the reallocation of laboratory resources to SARS-CoV-2 diagnostics. As a result of the suspension or reduction of routine screening programs for STIs, such as gonorrhea and chlamydia, in many areas, testing volumes temporarily decreased and diagnoses were delayed. The pandemic did, however, also hasten the uptake of point-of-care diagnostics, telemedicine, and self-collection kits, establishing the foundation for more accessible and decentralized STI testing.

The assays & kits segment is expected to be the largest during the forecast period

The assays & kits segment is expected to account for the largest market share during the forecast period. The extensive use of molecular diagnostic tests, like nucleic acid amplification tests (NAATs), which are very sensitive and specific for identifying CT/NG infections, is what is causing this dominance. Because of their simplicity of use, quick turnaround times, and compatibility with automated platforms, these assays are frequently utilized in clinical laboratories, hospitals, and even at-home testing kits. Moreover, assay-based solutions have become increasingly popular due to the increasing need for early and precise diagnosis, particularly in asymptomatic individuals. As a result, this market segment now accounts for the largest portion of market revenue.

The home care settings segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the home care settings segment is predicted to witness the highest growth rate. The primary drivers of this growth are the growing demands for STI screening that are accessible, convenient, and private. Telehealth-based diagnostic services and at-home sample collection kits have become increasingly popular, especially since the COVID-19 pandemic changed patient preferences. By enabling people to send samples to accredited labs and perform self-tests without having to visit medical facilities, these solutions improve testing frequency and lessen stigma. Additionally, self-testing's ease of use, growing awareness, and technological developments are anticipated to greatly speed up this market's growth.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, mainly due to the region's population size, rising STI rates, and growing sexual health consciousness. Furthermore, the region's market dominance is largely due to growing access to advanced diagnostic technologies in nations like China, India, Japan, and Australia, as well as expanding healthcare infrastructure and government initiatives supporting STI screening programs. The market in Asia-Pacific is expanding due to the growing use of point-of-care testing kits and nucleic acid amplification tests (NAATs), which has made the region the world's most prominent location for CT/NG testing.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, motivated by a robust healthcare system, a high level of knowledge about STDs, and the broad use of cutting-edge diagnostic tools. Strong reimbursement practices, expanding screening initiatives and continuous R&D efforts all contribute to the market's expansion. Additionally, variables supporting the strong growth of the CT/NG testing market in North America include the availability of highly sensitive and quick testing techniques, as well as rising public and private investments in sexual health programs.

Key players in the market

Some of the key players in CT/NG Testing Market include Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., Binx Health, Inc., Abbott Laboratories, Hologic Inc., Siemens Healthineers AG, ELITech Group SAS, Danaher Corporation, Seegene, Inc., Genetic Signatures Ltd., Becton, Dickinson and Company (BD), Qiagen N.V., Meridian Bioscience Inc. and PerkinElmer Inc.

Key Developments:

In February 2025, Bio-Rad Laboratories, Inc launched its TrailBlazer Tag and TrailBlazer StarBright Dye Label Kits. The new kits are designed to offer a convenient method to label any antibody with one of Bio-Rad's StarBright Dyes, for use in either flow cytometry or fluorescent western blot experiments. The new two-kit system provides researchers access to Bio-Rad's StarBright Blue and StarBright Violet Dyes, employing Bio-Rad's SpyTag and SpyCatcher technology to conjugate a dye to an antibody of choice.

In February 2025, Thermo Fisher Scientific Inc. announced that the company has entered into a definitive agreement with Solventum to acquire Solventum's Purification & Filtration business for approximately $4.1 billion in cash. Solventum's Purification & Filtration business is a leading provider of purification and filtration technologies used in the production of biologics as well as in medical technologies and industrial applications.

In November 2024, Roche announced that it has entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc, a public clinical-stage biopharmaceutical company pioneering donor-derived CAR-T cell therapies. Based in San Diego, California, Poseida's R&D portfolio includes pre-clinical and clinical-stage off-the-shelf CAR-T therapies across several therapeutic areas including haematological malignancies, solid tumours, and autoimmune disease, as well as manufacturing capabilities and technology platforms.

Products Covered:

  • Assays & Kits
  • Instruments/Analyzers

Testing Types Covered:

  • Laboratory Testing
  • Point-of-care (POC) Testing

End Users Covered:

  • Diagnostic Laboratories
  • Hospitals & Clinics
  • Home Care Settings
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global CT/NG Testing Market, By Product

  • 5.1 Introduction
  • 5.2 Assays & Kits
  • 5.3 Instruments/Analyzers

6 Global CT/NG Testing Market, By Testing Type

  • 6.1 Introduction
  • 6.2 Laboratory Testing
    • 6.2.1 Nucleic Acid Amplification Tests (NAAT)
    • 6.2.2 Immunoassays
    • 6.2.3 Culture Tests
  • 6.3 Point-of-care (POC) Testing
    • 6.3.1 Rapid Diagnostic Tests (RDT)
    • 6.3.2 Self-Testing Kits

7 Global CT/NG Testing Market, By End User

  • 7.1 Introduction
  • 7.2 Diagnostic Laboratories
  • 7.3 Hospitals & Clinics
  • 7.4 Home Care Settings
  • 7.5 Other End Users

8 Global CT/NG Testing Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Bio-Rad Laboratories, Inc.
  • 10.2 F. Hoffmann-La Roche Ltd.
  • 10.3 Thermo Fisher Scientific, Inc.
  • 10.4 Binx Health, Inc.
  • 10.5 Abbott Laboratories
  • 10.6 Hologic Inc.
  • 10.7 Siemens Healthineers AG
  • 10.8 ELITech Group SAS
  • 10.9 Danaher Corporation
  • 10.10 Seegene, Inc.
  • 10.11 Genetic Signatures Ltd.
  • 10.12 Becton, Dickinson and Company (BD)
  • 10.13 Qiagen N.V.
  • 10.14 Meridian Bioscience Inc.
  • 10.15 PerkinElmer Inc.

List of Tables

  • Table 1 Global CT/NG Testing Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global CT/NG Testing Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global CT/NG Testing Market Outlook, By Assays & Kits (2024-2032) ($MN)
  • Table 4 Global CT/NG Testing Market Outlook, By Instruments/Analyzers (2024-2032) ($MN)
  • Table 5 Global CT/NG Testing Market Outlook, By Testing Type (2024-2032) ($MN)
  • Table 6 Global CT/NG Testing Market Outlook, By Laboratory Testing (2024-2032) ($MN)
  • Table 7 Global CT/NG Testing Market Outlook, By Nucleic Acid Amplification Tests (NAAT) (2024-2032) ($MN)
  • Table 8 Global CT/NG Testing Market Outlook, By Immunoassays (2024-2032) ($MN)
  • Table 9 Global CT/NG Testing Market Outlook, By Culture Tests (2024-2032) ($MN)
  • Table 10 Global CT/NG Testing Market Outlook, By Point-of-care (POC) Testing (2024-2032) ($MN)
  • Table 11 Global CT/NG Testing Market Outlook, By Rapid Diagnostic Tests (RDT) (2024-2032) ($MN)
  • Table 12 Global CT/NG Testing Market Outlook, By Self-Testing Kits (2024-2032) ($MN)
  • Table 13 Global CT/NG Testing Market Outlook, By End User (2024-2032) ($MN)
  • Table 14 Global CT/NG Testing Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 15 Global CT/NG Testing Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 16 Global CT/NG Testing Market Outlook, By Home Care Settings (2024-2032) ($MN)
  • Table 17 Global CT/NG Testing Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 18 North America CT/NG Testing Market Outlook, By Country (2024-2032) ($MN)
  • Table 19 North America CT/NG Testing Market Outlook, By Product (2024-2032) ($MN)
  • Table 20 North America CT/NG Testing Market Outlook, By Assays & Kits (2024-2032) ($MN)
  • Table 21 North America CT/NG Testing Market Outlook, By Instruments/Analyzers (2024-2032) ($MN)
  • Table 22 North America CT/NG Testing Market Outlook, By Testing Type (2024-2032) ($MN)
  • Table 23 North America CT/NG Testing Market Outlook, By Laboratory Testing (2024-2032) ($MN)
  • Table 24 North America CT/NG Testing Market Outlook, By Nucleic Acid Amplification Tests (NAAT) (2024-2032) ($MN)
  • Table 25 North America CT/NG Testing Market Outlook, By Immunoassays (2024-2032) ($MN)
  • Table 26 North America CT/NG Testing Market Outlook, By Culture Tests (2024-2032) ($MN)
  • Table 27 North America CT/NG Testing Market Outlook, By Point-of-care (POC) Testing (2024-2032) ($MN)
  • Table 28 North America CT/NG Testing Market Outlook, By Rapid Diagnostic Tests (RDT) (2024-2032) ($MN)
  • Table 29 North America CT/NG Testing Market Outlook, By Self-Testing Kits (2024-2032) ($MN)
  • Table 30 North America CT/NG Testing Market Outlook, By End User (2024-2032) ($MN)
  • Table 31 North America CT/NG Testing Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 32 North America CT/NG Testing Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 33 North America CT/NG Testing Market Outlook, By Home Care Settings (2024-2032) ($MN)
  • Table 34 North America CT/NG Testing Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 35 Europe CT/NG Testing Market Outlook, By Country (2024-2032) ($MN)
  • Table 36 Europe CT/NG Testing Market Outlook, By Product (2024-2032) ($MN)
  • Table 37 Europe CT/NG Testing Market Outlook, By Assays & Kits (2024-2032) ($MN)
  • Table 38 Europe CT/NG Testing Market Outlook, By Instruments/Analyzers (2024-2032) ($MN)
  • Table 39 Europe CT/NG Testing Market Outlook, By Testing Type (2024-2032) ($MN)
  • Table 40 Europe CT/NG Testing Market Outlook, By Laboratory Testing (2024-2032) ($MN)
  • Table 41 Europe CT/NG Testing Market Outlook, By Nucleic Acid Amplification Tests (NAAT) (2024-2032) ($MN)
  • Table 42 Europe CT/NG Testing Market Outlook, By Immunoassays (2024-2032) ($MN)
  • Table 43 Europe CT/NG Testing Market Outlook, By Culture Tests (2024-2032) ($MN)
  • Table 44 Europe CT/NG Testing Market Outlook, By Point-of-care (POC) Testing (2024-2032) ($MN)
  • Table 45 Europe CT/NG Testing Market Outlook, By Rapid Diagnostic Tests (RDT) (2024-2032) ($MN)
  • Table 46 Europe CT/NG Testing Market Outlook, By Self-Testing Kits (2024-2032) ($MN)
  • Table 47 Europe CT/NG Testing Market Outlook, By End User (2024-2032) ($MN)
  • Table 48 Europe CT/NG Testing Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 49 Europe CT/NG Testing Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 50 Europe CT/NG Testing Market Outlook, By Home Care Settings (2024-2032) ($MN)
  • Table 51 Europe CT/NG Testing Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 52 Asia Pacific CT/NG Testing Market Outlook, By Country (2024-2032) ($MN)
  • Table 53 Asia Pacific CT/NG Testing Market Outlook, By Product (2024-2032) ($MN)
  • Table 54 Asia Pacific CT/NG Testing Market Outlook, By Assays & Kits (2024-2032) ($MN)
  • Table 55 Asia Pacific CT/NG Testing Market Outlook, By Instruments/Analyzers (2024-2032) ($MN)
  • Table 56 Asia Pacific CT/NG Testing Market Outlook, By Testing Type (2024-2032) ($MN)
  • Table 57 Asia Pacific CT/NG Testing Market Outlook, By Laboratory Testing (2024-2032) ($MN)
  • Table 58 Asia Pacific CT/NG Testing Market Outlook, By Nucleic Acid Amplification Tests (NAAT) (2024-2032) ($MN)
  • Table 59 Asia Pacific CT/NG Testing Market Outlook, By Immunoassays (2024-2032) ($MN)
  • Table 60 Asia Pacific CT/NG Testing Market Outlook, By Culture Tests (2024-2032) ($MN)
  • Table 61 Asia Pacific CT/NG Testing Market Outlook, By Point-of-care (POC) Testing (2024-2032) ($MN)
  • Table 62 Asia Pacific CT/NG Testing Market Outlook, By Rapid Diagnostic Tests (RDT) (2024-2032) ($MN)
  • Table 63 Asia Pacific CT/NG Testing Market Outlook, By Self-Testing Kits (2024-2032) ($MN)
  • Table 64 Asia Pacific CT/NG Testing Market Outlook, By End User (2024-2032) ($MN)
  • Table 65 Asia Pacific CT/NG Testing Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 66 Asia Pacific CT/NG Testing Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 67 Asia Pacific CT/NG Testing Market Outlook, By Home Care Settings (2024-2032) ($MN)
  • Table 68 Asia Pacific CT/NG Testing Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 69 South America CT/NG Testing Market Outlook, By Country (2024-2032) ($MN)
  • Table 70 South America CT/NG Testing Market Outlook, By Product (2024-2032) ($MN)
  • Table 71 South America CT/NG Testing Market Outlook, By Assays & Kits (2024-2032) ($MN)
  • Table 72 South America CT/NG Testing Market Outlook, By Instruments/Analyzers (2024-2032) ($MN)
  • Table 73 South America CT/NG Testing Market Outlook, By Testing Type (2024-2032) ($MN)
  • Table 74 South America CT/NG Testing Market Outlook, By Laboratory Testing (2024-2032) ($MN)
  • Table 75 South America CT/NG Testing Market Outlook, By Nucleic Acid Amplification Tests (NAAT) (2024-2032) ($MN)
  • Table 76 South America CT/NG Testing Market Outlook, By Immunoassays (2024-2032) ($MN)
  • Table 77 South America CT/NG Testing Market Outlook, By Culture Tests (2024-2032) ($MN)
  • Table 78 South America CT/NG Testing Market Outlook, By Point-of-care (POC) Testing (2024-2032) ($MN)
  • Table 79 South America CT/NG Testing Market Outlook, By Rapid Diagnostic Tests (RDT) (2024-2032) ($MN)
  • Table 80 South America CT/NG Testing Market Outlook, By Self-Testing Kits (2024-2032) ($MN)
  • Table 81 South America CT/NG Testing Market Outlook, By End User (2024-2032) ($MN)
  • Table 82 South America CT/NG Testing Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 83 South America CT/NG Testing Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 84 South America CT/NG Testing Market Outlook, By Home Care Settings (2024-2032) ($MN)
  • Table 85 South America CT/NG Testing Market Outlook, By Other End Users (2024-2032) ($MN)
  • Table 86 Middle East & Africa CT/NG Testing Market Outlook, By Country (2024-2032) ($MN)
  • Table 87 Middle East & Africa CT/NG Testing Market Outlook, By Product (2024-2032) ($MN)
  • Table 88 Middle East & Africa CT/NG Testing Market Outlook, By Assays & Kits (2024-2032) ($MN)
  • Table 89 Middle East & Africa CT/NG Testing Market Outlook, By Instruments/Analyzers (2024-2032) ($MN)
  • Table 90 Middle East & Africa CT/NG Testing Market Outlook, By Testing Type (2024-2032) ($MN)
  • Table 91 Middle East & Africa CT/NG Testing Market Outlook, By Laboratory Testing (2024-2032) ($MN)
  • Table 92 Middle East & Africa CT/NG Testing Market Outlook, By Nucleic Acid Amplification Tests (NAAT) (2024-2032) ($MN)
  • Table 93 Middle East & Africa CT/NG Testing Market Outlook, By Immunoassays (2024-2032) ($MN)
  • Table 94 Middle East & Africa CT/NG Testing Market Outlook, By Culture Tests (2024-2032) ($MN)
  • Table 95 Middle East & Africa CT/NG Testing Market Outlook, By Point-of-care (POC) Testing (2024-2032) ($MN)
  • Table 96 Middle East & Africa CT/NG Testing Market Outlook, By Rapid Diagnostic Tests (RDT) (2024-2032) ($MN)
  • Table 97 Middle East & Africa CT/NG Testing Market Outlook, By Self-Testing Kits (2024-2032) ($MN)
  • Table 98 Middle East & Africa CT/NG Testing Market Outlook, By End User (2024-2032) ($MN)
  • Table 99 Middle East & Africa CT/NG Testing Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 100 Middle East & Africa CT/NG Testing Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 101 Middle East & Africa CT/NG Testing Market Outlook, By Home Care Settings (2024-2032) ($MN)
  • Table 102 Middle East & Africa CT/NG Testing Market Outlook, By Other End Users (2024-2032) ($MN)